Scancell Holdings Plc Issue of Equity (2314P)
08 February 2023 - 6:00PM
UK Regulatory
TIDMSCLP
RNS Number : 2314P
Scancell Holdings Plc
08 February 2023
8 February 2023
Scancell Holdings plc
("Scancell" or the "Company")
Exercise of Share Options and Admission of New Ordinary
Shares
Scancell Holdings plc (AIM: SCLP), the developer of novel
immunotherapies, today announces that it has issued 3,184,630 new
ordinary shares of 0.1p each in the share capital of the Company
("Ordinary Shares"), pursuant to the exercise of share options by
Ichor Medical Systems Inc. at an exercise price of 4.5p per
Ordinary Share.
An application for the admission of the 3,184,630 Ordinary
Shares to trading on AIM ("Admission") has been made. It is
expected that Admission will become effective on or around 13
February 2023.
The new Ordinary Shares will rank pari passu with the Company's
existing Ordinary Shares. The total number of Ordinary Shares in
issue following Admission will be 818,403,461. This number may be
used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in the Company under the
FCA's Disclosure Guidance and Transparency Rules.
For further information, please contact:
Scancell Holdings plc +44 (0) 20 3727 1000
Dr Jean-Michel Cosséry, Non-Executive
Chairman +44 (0) 20 7886 2500
Professor Lindy Durrant, CEO
Stifel Nicolaus Europe Limited (Nominated
Adviser and Joint Broker) +44 (0) 20 7710 7600
Nicholas Moore/Samira Essebiyea/William Palmer-Brown
(Healthcare Investment Banking)
Nick Adams/Nick Harland (Corporate Broking)
Panmure Gordon (UK) Limited (Joint Broker) +44 (0) 20 7886 2500
Freddy Crossley/Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
FTI Consulting +44 (0) 20 3727 1000
Simon Conway/Rob Winder/Alex Davis
About Scancell
Scancell is a clinical stage biopharmaceutical company that is
leveraging its proprietary research, built up over many years of
studying the human adaptive immune system, to generate novel
medicines to treat significant unmet needs in cancer and infectious
disease. The Company is building a pipeline of innovative products
by utilising its four technology platforms: Moditope(R) and
ImmunoBody(R) for vaccines and GlyMab(R) and AvidiMab(R) for
antibodies.
Adaptive immune responses include antibodies and T cells (CD4
and CD8), both of which can recognise damaged or infected cells. In
order to destroy such cancerous or infected cells, Scancell uses
either vaccines to induce immune responses or monoclonal antibodies
(mAbs) to redirect immune cells or drugs. The Company's unique
approach is that its innovative products target modifications of
proteins and lipids. For the vaccines (Moditope(R) and
ImmunoBody(R) ) this includes citrullination and homocitrullination
of proteins, whereas its mAb portfolio targets glycans or sugars
that are added onto proteins and / or lipids (GlyMab(R) ) or
enhances the potency of antibodies and their ability to directly
kill tumour cells (AvidiMab(R) ).
For further information about Scancell, please visit:
https://www.scancell.co.uk/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEEAFAXEFNDEAA
(END) Dow Jones Newswires
February 08, 2023 02:00 ET (07:00 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2023 to Apr 2024